Ongoing clinical trials for HNSCC include HMBD-001 (antibody against HER3) [16], Lenvatinib (antibody against multiple receptors of tyrosine kinases) [17], therapeutic vaccines against HPV-related antigens [18, 19], adoptive cell therapy [20] and other immunotherapies [21]. This evidence concerns the gene ERBB3 and head and neck squamous cell carcinoma.